Brismed Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.15 M
- Paid Up Capital ₹ 0.15 M
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 376.99%
- Profit Growth 93.62%
- Ebitda 127.68%
- Net Worth -5.77%
- Total Assets -17.45%
About Brismed Pharma
Brismed Pharma Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 November 2020 (Four years and three months 0 days old ). Its registered office is in Palakkad, Kerala, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.15 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Moideen Vengadan, Byju Parengal, and Rappai Ouseph serve as directors at the Company.
Company Details
-
Location
Palakkad, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KL2020PTC065657
-
Company No.
065657
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Nov 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Brismed Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Moideen Vengadan
|
Managing Director | 24-Feb-2021 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Byju Parengal
|
Director | 22-Dec-2022 | Current |
|
Rappai Ouseph
|
Director | 02-Mar-2023 | Current |
Financial Performance of Brismed Pharma.
Brismed Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 376.99% increase. The company also saw a substantial improvement in profitability, with a 93.62% increase in profit. The company's net worth dipped by a decrease of 5.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brismed Pharma?
Unlock access to Brismed Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brismed Pharma?
Brismed Pharma has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brismed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brismed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
